RNAC insider transaction filings
Cartesian Therapeutics, Inc. — 50 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-04-06. Screen RNAC transaction legs live →
Insider transaction summary — last 90 days
No Form 4 filings for RNAC between 2026-06-24 and 2026-09-22. The table below lists the most recent filings on record.
Recent Form 4 filings — Cartesian Therapeutics, Inc.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-04-06 | 4 | Hoge Elizabeth — 10% owner Seven One Eight Three Four Irrevocable Trust — 10% owner | Option exercise (M): 758,001 · Option exercise (M): 22,740.03 (derivative) | EDGAR |
| 2026-04-06 | 4 | Kalayoglu Murat — 10% owner | Option exercise (M): 758,001 · Option exercise (M): 22,740.03 (derivative) | EDGAR |
| 2026-03-13 | 4 | Singer Michael — Director | Gift (G): 6,555 @ $0 | EDGAR |
| 2026-01-08 | 4 | Brunn Carsten — President and CEO, Director | Sale (S): 23,766 @ $6.82 | EDGAR |
| 2026-01-08 | 4 | Miljkovic Milos — Chief Medical Officer | Sale (S): 3,573 @ $6.82 | EDGAR |
| 2026-01-08 | 4 | Davis Blaine — Chief Financial Officer | Sale (S): 10,591 @ $6.82 | EDGAR |
| 2026-01-06 | 4 | DeSilva Nishan M — Director | Grant/award (A): 2,600 @ $0 · Grant/award (A): 7,800 (derivative) @ $0 | EDGAR |
| 2026-01-06 | 4 | Brunn Carsten — President and CEO, Director | Grant/award (A): 143,200 @ $0 · Grant/award (A): 415,700 (derivative) @ $0 | EDGAR |
| 2026-01-06 | 4 | Malik Kemal — Director | Grant/award (A): 2,600 @ $0 · Grant/award (A): 7,800 (derivative) @ $0 | EDGAR |
| 2026-01-06 | 4 | Miljkovic Milos — Chief Medical Officer | Grant/award (A): 27,000 @ $0 · Grant/award (A): 77,000 (derivative) @ $0 | EDGAR |
| 2026-01-06 | 4 | Seymour June Ann — Chief Accounting Officer | Grant/award (A): 6,500 @ $0 · Grant/award (A): 19,000 (derivative) @ $0 | EDGAR |
| 2026-01-06 | 4 | Davis Blaine — Chief Financial Officer | Grant/award (A): 37,000 @ $0 · Grant/award (A): 109,000 (derivative) @ $0 | EDGAR |
| 2026-01-06 | 4 | English Emily — Chief Operations Officer | Grant/award (A): 24,000 @ $0 · Grant/award (A): 71,000 (derivative) @ $0 | EDGAR |
| 2026-01-06 | 4 | Singer Michael — Director | Grant/award (A): 2,600 @ $0 · Grant/award (A): 7,800 (derivative) @ $0 | EDGAR |
| 2026-01-06 | 4 | Kalayoglu Murat — Director, 10% owner | Grant/award (A): 2,600 @ $0 · Grant/award (A): 7,800 (derivative) @ $0 | EDGAR |
| 2026-01-06 | 4 | BARABE TIMOTHY C — Director | Grant/award (A): 2,600 @ $0 · Grant/award (A): 7,800 (derivative) @ $0 | EDGAR |
| 2026-01-06 | 4 | ZENNER PATRICK J — Director | Grant/award (A): 2,600 @ $0 · Grant/award (A): 7,800 (derivative) @ $0 | EDGAR |
| 2026-01-06 | 4 | SPRINGER TIMOTHY A — Director, 10% owner | Grant/award (A): 2,600 @ $0 · Grant/award (A): 7,800 (derivative) @ $0 | EDGAR |
| 2026-01-02 | 4 | English Emily — Chief Operations Officer | Option exercise (M): 7,500 @ $3.30 · Option exercise (M): 7,500 (derivative) | EDGAR |
| 2025-12-18 | 4 | Bot Adrian Ion — Director | Grant/award (A): 5,800 @ $0 · Grant/award (A): 17,200 (derivative) @ $0 | EDGAR |
| 2025-12-08 | 4 | BARABE TIMOTHY C — Director | Purchase (P): 30,000 @ $6.86 | EDGAR |
| 2025-12-02 | 4 | English Emily — Chief Operations Officer | Option exercise (M): 7,500 @ $3.30 · Option exercise (M): 7,500 (derivative) | EDGAR |
| 2025-11-19 | 4 | Singer Michael — Director | Gift (G): 20,000 @ $0 | EDGAR |
| 2025-10-28 | 4 | Seymour June Ann — Chief Accounting Officer | Grant/award (A): 50,000 (derivative) @ $0 | EDGAR |
| 2025-05-14 | 4 | English Emily — Chief Operations Officer | Option exercise (M): 7,500 @ $3.30 · Option exercise (M): 7,500 (derivative) | EDGAR |
| 2025-04-16 | 4 | English Emily — Chief Operations Officer | Option exercise (M): 7,500 @ $3.30 · Option exercise (M): 7,500 (derivative) | EDGAR |
| 2025-04-11 | 4 | SPRINGER TIMOTHY A — Director, 10% owner | Purchase (P): 7,342 @ $9.43 · Purchase (P): 31 @ $9.95 · Purchase (P): 41,604 @ $9.43 · Purchase (P): 178 @ $9.95 · Purchase (P): 7,966 @ $10.43 · Purchase (P): 609 @ $10.92 · +4 more | EDGAR |
| 2025-03-20 | 4 | SPRINGER TIMOTHY A — Director, 10% owner | Purchase (P): 14,740 @ $14.42 · Purchase (P): 20,234 @ $14.97 · Purchase (P): 54,889 @ $15.59 | EDGAR |
| 2025-01-15 | 4 | SPRINGER TIMOTHY A — Director, 10% owner | Purchase (P): 7,962 @ $16.86 · Purchase (P): 8,983 @ $17.78 · Purchase (P): 4,022 @ $18 | EDGAR |
| 2025-01-13 | 4 | Jewell Christopher M — Chief Scientific Officer | Option exercise (M): 9,000 @ $3.23 · Option exercise (M): 9,000 (derivative) | EDGAR |
| 2025-01-07 | 4 | Kurtoglu Metin — Chief Technology Officer | Sale (S): 2,417 @ $16.72 · Sale (S): 2,458 @ $16.83 | EDGAR |
| 2025-01-07 | 4 | Miljkovic Milos — Chief Medical Officer | Sale (S): 932 @ $16.72 · Sale (S): 948 @ $16.83 | EDGAR |
| 2025-01-07 | 4 | Jewell Christopher M — Chief Scientific Officer | Sale (S): 1,264 @ $16.72 · Sale (S): 1,286 @ $16.83 | EDGAR |
| 2025-01-07 | 4 | English Emily — Chief Operations Officer | Sale (S): 891 @ $16.72 · Sale (S): 906 @ $16.83 | EDGAR |
| 2025-01-07 | 4 | Brunn Carsten — President and CEO, Director | Sale (S): 8,563 @ $16.72 · Sale (S): 8,708 @ $16.83 | EDGAR |
| 2025-01-07 | 4 | Davis Blaine — Chief Financial Officer | Sale (S): 3,961 @ $16.72 · Sale (S): 4,028 @ $16.83 | EDGAR |
| 2025-01-06 | 4 | Kurtoglu Metin — Chief Technology Officer | Grant/award (A): 16,100 @ $0 · Grant/award (A): 47,400 (derivative) @ $0 | EDGAR |
| 2025-01-06 | 4 | Brunn Carsten — President and CEO, Director | Grant/award (A): 57,500 @ $0 · Grant/award (A): 169,100 (derivative) @ $0 | EDGAR |
| 2025-01-06 | 4 | Jewell Christopher M — Chief Scientific Officer | Grant/award (A): 16,100 @ $0 · Grant/award (A): 47,400 (derivative) @ $0 | EDGAR |
| 2025-01-06 | 4 | English Emily — Chief Operations Officer | Grant/award (A): 16,100 @ $0 · Grant/award (A): 47,400 (derivative) @ $0 | EDGAR |
| 2025-01-06 | 4 | Davis Blaine — Chief Financial Officer | Grant/award (A): 22,000 @ $0 · Grant/award (A): 64,600 (derivative) @ $0 | EDGAR |
| 2025-01-06 | 4 | Miljkovic Milos — Chief Medical Officer | Grant/award (A): 19,000 @ $0 · Grant/award (A): 56,000 (derivative) @ $0 | EDGAR |
| 2025-01-06 | 4 | Kalayoglu Murat — Director, 10% owner | Grant/award (A): 2,600 @ $0 · Grant/award (A): 7,800 (derivative) @ $0 | EDGAR |
| 2025-01-06 | 4 | Malik Kemal — Director | Grant/award (A): 2,600 @ $0 · Grant/award (A): 7,800 (derivative) @ $0 | EDGAR |
| 2025-01-06 | 4 | Singer Michael — Director | Grant/award (A): 2,600 @ $0 · Grant/award (A): 7,800 (derivative) @ $0 | EDGAR |
| 2025-01-06 | 4 | DeSilva Nishan M — Director | Grant/award (A): 2,600 @ $0 · Grant/award (A): 7,800 (derivative) @ $0 | EDGAR |
| 2025-01-06 | 4 | BARABE TIMOTHY C — Director | Grant/award (A): 2,600 @ $0 · Grant/award (A): 7,800 (derivative) @ $0 | EDGAR |
| 2025-01-06 | 4 | ZENNER PATRICK J — Director | Grant/award (A): 2,600 @ $0 · Grant/award (A): 7,800 (derivative) @ $0 | EDGAR |
| 2025-01-06 | 4 | COX CARRIE SMITH — Director | Grant/award (A): 2,600 @ $0 · Grant/award (A): 8,000 (derivative) @ $0 | EDGAR |
| 2025-01-06 | 4 | SPRINGER TIMOTHY A — Director, 10% owner | Grant/award (A): 2,600 @ $0 · Grant/award (A): 7,800 (derivative) @ $0 | EDGAR |
Recent 8-K events — Cartesian Therapeutics, Inc.
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-08-06 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-17 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders | EDGAR |
| 2026-06-09 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-26 | 8-K | 1.01 — Entry into a Material Definitive Agreement 2.03 — Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant 3.02 — Unregistered Sales of Equity Securities 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-04-30 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-03-30 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | EDGAR |
| 2026-03-09 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-01-09 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-12-18 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 5.05 — Amendments to the Registrant's Code of Ethics, or Waiver of a Provision of the Code of Ethics 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-11-13 | 8-K | 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=RNAC returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →